Journal
JOURNAL OF MATERIALS CHEMISTRY B
Volume 6, Issue 38, Pages 6108-6121Publisher
ROYAL SOC CHEMISTRY
DOI: 10.1039/c8tb01788c
Keywords
-
Categories
Funding
- National Natural Science Foundation of China [81573364]
Ask authors/readers for more resources
Sonodynamic therapy (SDT) kills tumor cells by converting molecular oxygen (O-2) into reactive oxygen species (ROS) using sonosensitizers and appropriate ultrasound (US) stimulation. However, pre-existing tumorous hypoxia severely limits SDT efficacy. Worse is that O-2 consumption during SDT will aggravate local hypoxia. In this study, we developed an O-2 self-supplied and lossless US-responsive detonation strategy to overcome the above limitation. This explores a perfluorohexane (PFH) bubbling-based stealth camouflage and a US-controlled on-demand system (RBC-HPBs/HMME/PFH) to realize US imaging-guided precise drug delivery and locally positioning tumor therapy. Compared with HPBs/HMME/PFH, the results showed that RBC encapsulation can promote cell phagocytosis. After US stimulation, the PFH phase change induced RBC instantaneous blasting. Simultaneous release of HMME and O-2 resulted in plenty of ROS production and the intracellular redox system imbalance, significantly enhancing their cytotoxicity. Following US imaging guidance, the greatly improved local ROS level and the anti-tumor effect were proved in 4T1 tumor-bearing mice for HMME and the O-2 synchronous co-transport system. Immunohistochemistry results proved that RBC-HPBs/HMME/PFH + US could significantly relieve tumorous hypoxia and reduce the microvessel density as an O-2 reservoir, which would block nutritional sources to starve tumor cells and inhibit their metastasis, achieving a cancer multi-mechanism treatment.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available